

Page 1/16

COMPANY UPDATE

MedLife SA

Accumulate

Analyst: Caius Rapanu +4 0373 510 441 caiusroa.rapanu@bcr.ro

Share price (RON) close as of 20/03/2025	5.94	Reuters	ROM.BX	Free float	59.0%
Number of shares (mn)	531.5	Bloomberg	M RO	Shareholders	Marcu Mihail (15.8%)
Market capitalization (RON mn / EUR mn)	3,157 / 634	Div. Ex-date	11/04/24	Cristescu Mi	haela Gabriela (14.04%)
Enterprise value (RON mn / EUR mn)	3,908 / 785	Target price	6.65	Homepage:	www.medlife.ro

Key figures Overview

RON mn	2023	2024	2025e	2026e
Net sales EBITDA EBIT EBT Net profit	2,211.6 289.8 91.4 4.2 -4.2	2,626.2 378.2 130.7 28.5 23.9	2,946.8 434.7 176.7 105.3 88.5	3,301.3 525.7 261.4 223.1 187.4
EPS (RON) CEPS (RON) BVPS (RON) Dividend/Share (RON)	-0.01 0.35 0.90	0.04 0.90 0.97	0.17 0.84 1.13	0.35 0.88 1.46
EV/EBITDA (x) P/E (x) P/CE (x) Dividend yield (%)	10.93 nm 11.53	11.13 128.90 6.42	8.99 35.68 7.06	6.53 16.85 6.77
EBITDA margin (%) Operating margin (%) Net profit margin (%)	13.11 4.13 -0.19	14.40 4.98 0.91	14.75 5.99 3.00	15.93 7.92 5.68

Trading data & Statistics

-MedLife SA

-BET

4.0

3.5

Trading data & otationoo			
Daily averages	5 days	30 days	last year
Volume	244,069	129,004	166,282
Trading value (RON mn)	1.4	0.8	0.9
6.5			
6.0 - Mmm	y Mymm	MMM	mm
5.5 -		ųν	
5.0 -			
4.5 -	1 mm	~~~~~~	m

DJ EURO STOXX Health Care

 Price performance:
 1M
 3M
 6M
 12M

 in EUR
 1.9%
 -0.9%
 -3.5%
 53.4%

Financial Strength

	2023	2024	2025e	2026e
ROE (%)	-0.88	4.81	15.84	27.22
ROCE (%)	-5.23	5.52	7.77	13.49
Equity ratio (%)	18.25	17.33	21.30	27.86
Net debt (RON mn)	1,052.44	1,124.86	751.32	273.94
Gearing (%)	220.13	217.69	125.19	35.27

Continuing to build for the future

We maintain our Accumulate recommendation and RON6.65/share target price following 2024 results that were in line with our expectations.

The company has shown it can maintain an adequate profitability level, especially on an EBITDA level, and continue to grow, both organically and via acquisitions.

We are impressed with the continuing trend of increasing sophistication of services offered, with inroads in AI, digitalization and technology that are premiers in the country and the region.

The strategic concentration on oncology, chronic disease and other types of care where demand does not depend on the economic cycle should offer a degree of hedging to macro volatility. This complements naturally the significant pricing power of the company, that is predicated both on range and complexity of service.

Management stated objectives include a continuing concentration on margin consolidation, while pursuing an opportunistic acquisition policy and further organic growth.

We also expect margin consolidation to fuel a mediumterm virtuous cycle of bottom line appreciation, with a shift to profit rather than turnover taxation.

Medlife 2024 results: robust in top line and profitability

MedLife 2024 results show a significant boost in top line, with consolidated sales increasing by 23%. At the same time, operating expensed grew by only 21.2%, leading to an operating profit approximately 56% higher than that of 2023, and to an EBITDA that was 36% higher. Net income jumped significantly, reverting the negative result obtained in 2023, registering a positive RON18.4mn FY24 while EBITDA margin advanced from 13.0% to 14.4%.

INCOME ST. (RON, mn.)	4Q24	4Q23	chng (%)	3Q24	chng (%)	4Q22	chng (%)	2024	2023	chng (%)	2022	chng (%)
Sales	737	583.0	26%	668.3	10%	471.5	56%	2715.5	2210.4	23%	1795.4	51%
Other operating income	3	(1.6)	n.m.	2.1	51%	4.2	-24%	9.0	11.3	-20%	14.1	-36%
Operating income	740	581.5	27%	670.4	10.4%	475.7	56%	2724.5	2221.7	22.6%	1809.6	51%
Operating expenses	(711)	(566.7)	25%	(635.9)	11.7%	(476.9)	49%	(2582.1)	(2130.2)	21.2%	(1715.3)	51%
Operating profit	29	14.7	100%	34.5	-15%	(1.2)	n.m.	142.4	91.5	56%	94.2	51%
EBITDA	102	71.2	43%	96.7	5%	48.6	110%	391.7	288.9	36%	246.6	59%
Financial result	(23)	(25.6)	-10%	(25.6)	-10%	(16.8)	37%	(98.1)	(87.2)	12%	(44.7)	120%
Profit before taxes	6	(10.9)	-159%	8.9	-28%	(18.0)	-136%	44.3	4.3	931%	49.6	-11%
Income tax	(9)	2.9	-407%	(5.5)	61%	(1.4)	539%	(26.0)	(8.5)	207%	(12.1)	114%
Net profit	(2)	(8.0)	n.m.	3.4	n.m.	(19.4)	-87%	18.4	(4.2)	n.m.	37.4	-51%
EBITDA margin	13.8%	12.2%		14.4%		10.2%		14.4%	13.0%		13.6%	
Net margin	-0.3%	-1.4%		0.5%		-4.1%		0.7%	-0.2%		2.1%	
Operating margin	4.00%	2.52%		5.16%		5%		5.24%	4.14%		5.25%	

Source: Company data, Erste Group Research

Similar story on a quarterly basis

On a y-o-y basis, the picture was similar, with 4Q24 top line increasing by 27%, while costs grew only 25%, resulting in an operating profit that was double than that of the previous year's fourth quarter and a significant improvement in net income as well (a loss of RON 2mn vs. the loss of RON 8mn of the same period last year). Profitability increased, with EBITDA margin up from 12.2% to 13.8%. Vs the previous quarter the growth in top line, of 10% was exceeded by the growth in costs, of 11.7%, leading to a 15% decline in EBIT q-o-q, and a decline in net income as well (as mentioned above, RON 2mn loss compared to the positive net result from 3Q24). Nevertheless, profitability remained decent, with EBITDA margin only slightly lower compared to that of the previous quarter.

Pro-forma profitability looks slightly better...

The company issues every quarter also a pro-forma abridged income statement, adjusted with the historical financial results of the companies acquired by during the period and other one-off items. This statement transposes the acquisitions as if they happened at the beginning of the year by combining the financial results for the period of the acquired companies with those of the group and the elimination of certain expenses included in the consolidated I/S which the company considers to be non-operational and/or non-recurring by nature. The Consolidated Pro Forma PL provides a hypothetical illustration of the impact of the transactions on the Company's earnings. The company is trying to illustrate the effect of the acquisitions completed in any given period and provide an estimate of recurring EBITDA. Furthermore, the consolidated figures (IFRS) include the full amount of debt incurred to finance the acquisitions completed as of the acquisitions.

... on consolidation of acquisitions

During 2024, the following acquisitions took place: Personal Genetics SRL(solid expertise with a large network of laboratories at national level), Med Varix SRL(solid expertise in the treatment of varicose veins), VP-MED Hungary(which primarily offers modern varicose vein surgical procedures, Euromedica Hospital SA and Euromedica Administrator SA(a medium sized hospital in Baia Mare), Centrul Medical Antares SRL(very important private medical services provider in the region of Moldova, Provita 2000

Medical Center (local medical center in Constanta) and Routine Med Group(solidifying its presence in SE of Romania). Normalization was also performed for excluding the impact of one-off costs, such as early stage investments that are loss-making before operating, external consultancy & due diligence related to acquisitions (including aborted one) and other nonrecurring costs.

	Rev. (F	RON, mn) l	FRS	Adjustr	nent	Profo	rma	
Bussiness line	2024	2023 0	:hng (%)	2024	2023	2024	2023 0	:hng (%)
Clinics	1022.4	831.2	23.0%	-39.8	-38.3	982.6	792.9	23.9%
Stomatology	125.5	121.8	3.1%	0.0	0.0	125.5	121.8	3.1%
Hospitals	661.5	480.5	37.7%	-122.7	-68.8	538.7	411.7	30.9%
Laboratories	295.4	230.7	28.0%	7.7	3.9	303.1	234.5	29.2%
Corporate	297.0	259.5	14.4%	0.0	0.6	297.0	260.1	14.2%
Pharmacies	69.2	60.7	14. 0 %	0.0	0.0	69.2	60.7	14 .0 %
Other	244.5	226.1	8.2%	0.0	0.0	244.5	226.1	8.1%
Total	2715.5	2210.4	22.8%	-154.8	-102.7	2560.7	2107.8	21.5%

Source: Company data, Erste Group Research

When deducting the RON163mn subsidies received at group level (clinics and hospitals) from the National Health Program for chemotherapy drugs and adding a positive RON7.7mn from laboratories, and make a similar adjustment for YE23, (RON107mn and RON4mn respectively), the net impact is a sales increase of RON453mn vs. 2023. The proforma expenses are also diminished by the costs related to the National Health Program for oncology (RON 158.6mn) and RON 13mn one-offs and nonrecurrent costs, related to acquisitions. Under this representation, the profitability of the group was marginally better, with EBITDA reaching RON 412mn and EBITDA margin at 16%, compared to 14.4% under IFRS while net margin increased marginally to 1.3%, compared to a 0.7% net margin under IFRS.

	IFR	s		Adjust	m.	Profo	rma	
INCOME ST. (RON, mn.)	2024	2023	chng (%)	2024	2023	2024	2023	chng (%)
Sales	2,715.5	2,210.4	23%	(154.8)	(102.7)	2,560.7	2,107.7	21%
Other operating income	9.0	11.3	-20%	1.2	1.0	10.2	12.3	-17%
Operating income	2,724.5	2,221.7	22.6%	(153.6)	(101.7)	2,570.9	2,120.0	21%
Operating expenses	(2,582.1)	(2,130.2)	21.2%	171.6	127.1	(2,410.5)	(2,003.1)	20%
Operating profit	142.4	91.5	56%	18.0	25.4	160.4	116.9	37%
EBITDA	391.7	288.9	36%	20.6	28.2	412.3	317.1	30%
Financial result	(98.1)	(87.2)	12%	(0.9)	(0.9)	(99.0)	(88.1)	12%
Profit before taxes	44.3	4.3	931%	17.1	24.5	61.4	28.8	113%
Income tax	(26.0)	(8.5)	207%	(2.6)	(3.8)	(28.6)	(12.3)	133%
Net profit	18.4	(4.2)	-541%	14.5	20.7	32.9	16.5	99%
EBITDA margin	14.4%	13.0%				16.0%	15.0%	
Net margin	0.7%	-0.2%				1.3%	0.8%	
Operating margin	5.2%	4.1%				6.2%	5.5%	


Source: Company data, Erste Group Research


Top line growth

Under IFRS and pro-forma, all main business segments registered significant growth in revenues during the semester on a y-o-y basis. The largest expansion in relative numbers was registered in hospitals, on the back of openings, and tariffs, followed by laboratories, clinics, and corporates. Thus, hospitals' revenues grew around 38% compared to 2023, while clinics' revenues increased by 23%, laboratories by 28% and corporates by 14% respectively. Pharmacies revenues grew by about 14%, while stomatology revenues increased by 3%. Generally, the clinics remained the largest contributor of the group, with more than 37% share of total revenues, while hospitals increased as a share of total revenues to around 24% from 21% in 2023. Laboratories and corporate revenues accounted for more or less the same share of total revenues of about 11%.




Page 4/16





 Clinics = Stomatology = Hospitals = Laboratories = Corporate = Pharmacies = Other Source: Company data, Erste Group Research



Business line revenues YE24 (ext.)

Clinics Stomatology Hospitals Laboratories Corporate Pharmacies Other

High unit hikes in largest contributor segments...

During YE24, from the main revenue generators of the company, the largest growth in number of client visits were recorded in the hospitals segment, 18.5%, as a result of acquisitions and organic growth, but also the introduction and expansion of robotic surgery. In the clinics segment, the increase was also significant, by 13%, under the consolidation of acquisitions and higher demand for outpatient services. A 18% growth was registered in the laboratories' segment. Small 2% advancement in pharmacies' segment, while stomatology visits and corporate subscriptions have diminished very lightly.

	Re	v. (RON, m	n)	U	Units ('000) Avg. fees (RON			N)	
Bussiness line	2024	2023 c	:hng (%)	2024	4 2023 chng (%) 2024		2024	4 2023 chng	
Clinics	1022.4	831.2	23.0%	4334.3	3834.1	13.0%	235.9	216.8	8.8%
Stomatology	125.5	121.8	3.1%	185.6	185.8	-0.1%	676.4	655.3	3.2%
Hospitals	661.5	480.5	37.7%	164.9	139.2	18.5%	4010.5	3450.7	16.2%
Laboratories	295.4	230.7	28.0%	8766.2	7424.3	18.1%	33.7	31.1	8.4%
Corporate	297.0	259.5	14.4%	872.0	873.0	-0 .1%	340.6	297.2	14.6%
Pharmacies	69.2	60.7	14.0%	478.1	468.9	2.0%	144.8	129.5	11. 9 %
Other	244.5	226.1	8.2%						
Total	2.715.5	2.210.4	22.8%						

Total2,715.52,210.422.8%Source: Company data, Erste Group Research

...and growth in fees across all business lines

On a yearly basis, the average fees showed an overall healthy picture across all segments. The increase among main contributors, was 8.8% recorded in the clinics segment. In the hospitals segment, the average fees increased by 16.2%. In the corporate segment the average fee growth was about 14.6%, and in laboratories by 8.4%, and in pharmacies it grew by about 11.2%. In the stomatology segment, the average fee did grow by 3%, reversing the slight decline previously noted (in 9M24 results).

	Rev	. (RON, m	n)	ι	Jnits ('000)	Avg. fees (RON)			
Bussiness line	4Q24	4Q23 c	4Q23 chng (%)		4Q23			4Q23 c	hng (%)	
Clinics	280.7	223.0	25.8%	1,153.2	996.8	15.7%	243.4	223.8	8.8%	
Stomatology	30.5	29.3	4.2%	43.1	47.7	-9.6%	707.3	613.9	15.2%	
Hospitals	192.8	127.3	51.4%	47.1	36.3	29.7%	4096.9	3509.8	16.7%	
Laboratories	69.5	58.9	17.9%	2,152.7	1,960.4	9.8%	32.3	30.1	7.4%	
Corporate	72.4	70.1	3.3%	872.0	873.0	-0.1%	83.1	80.3	3.4%	
Pharmacies	18.8	14.4	30.6%	134.0	122.4	9.5%	140.6	117.8	19.3%	
Other	72.1	60.0	20.3%							

Total 736.8 583.0 26.4%

Source: Company data, Erste Group Research

Quarterly dynamics: a similar positive trend, y-o-y

On a quarterly basis, the 4Q results show a similar picture y-o-y. The revenue growth for clinics registered almost 26%, on the back of a 15.7% increase in visits and a 8.8% increase in average fees. Significant growth in the hospital segment, which registered a major 29.7% jump in patients and a 16.7% jump in average fees, leading to a more than 51% growth in revenues. Good growth in revenues has been posted by the laboratories as well, on the back of an increase in patients (almost 10%) and a 7.4% increase in average fees. The pharmacies' segment also grew in revenues by more than 30% on a combination of higher units and slightly higher average fees. The corporate segment revenues increased by 3.3%, on minor decrease in number of subscriptions, but slightly higher average fees. The dentistry segment grew about 4%, registering a 9.6% decline in patients on 15.2% growth in average fees.

	Rev	. (RON, m	n)	ι	Jnits ('000))	Avg.	fees (RO	N)
Bussiness line	4Q24	3Q24 o	chng (%)	4Q24	3Q24	chng (%)	4Q24	3Q24 o	chng (%)
Clinics	280.7	254.0	10.5%	1,153.2	1,084.1	6.4%	243.4	234.3	3.9%
Stomatology	30.5	29.4	3.6%	43.1	44.0	-2.0%	707.3	669.2	5.7%
Hospitals	192.8	151.0	27.7%	47.1	37.6	25.2%	4096.9	4017.8	2.0%
Laboratories	69.5	79.9	-13.1%	2,152.7	2,281.5	-5.6%	32.3	35.0	-7.9%
Corporate	72.4	73.8	-1.9%	872.0	885.4	-1.5%	83.1	83.4	-0.4%
Pharmacies	18.8	17.0	10.8%	134.0	105.7	26.8%	140.6	160.9	-12.6%
Other	72.1	63.2	14.0%						
Total	736.8	668.4	10.2%						

Source: Company data, Erste Group Research

Q-o-q figures are slightly weaker, though still growing

Comparing the 4Q24 q-o-q figures to the previous quarter, a slightly different picture emerges. The average fees increased for clinics by 3.9%, 5.7% in stomatology and 2% in the hospitals segment, while the rest actually declined. Laboratories average fees diminished by 7.9%, corporates marginally contracted by 0.4%, while in the pharmacies segment the fees declined by 12%. In terms of number of patients, the clinics experienced an increase of 6.4%, the hospitals' segment recorded a strong 25% increase in patients and the pharmacies saw a hefty increase in units as well (almost 27%). The laboratories, stomatology and corporates declined slightly showing a slightly weaker seasonality. However altogether, revenues (IFRS) increased 10.2%.


Higher average fees for more complex services.

Looking at the quarterly evolution of drivers averaging the last quarters, compared to the previous periods, we believe the company has maintained solid pricing power, albeit most increasing fees, come on the back of more complex procedures. This may be the harbinger of a leaner period in terms of fees increases, especially considering the postelection more austere economic environment. Nevertheless, we believe the management of MedLife has made an appropriate choice, by opting for a permanent increase in the complexity of services and of maintaining and attracting valuable personnel.

CAGR of drivers remains solid

When plotting the multiannual evolution of main drivers, it is notable that the acquisition spree of the company has resulted in adding expansion growth to the organic growth in terms of units (visits/patients) especially in the main revenue contributors. Thus, the 4Q unit CAGR between 2017 and 2024 in terms of clinics is a staggering 21.2%, and that of hospitals is 22.5%. All segments have seen a major increase in units with the corporate segment (which is the lowest in increases) at a very solid 6.3%.


Page 6/16



Source: Company data, Erste Group Research

While pricing power still a major earnings driver


The superior pricing power of the company remains an important driver, that has seen steady growth, with little variations over the last seven years, with certain larger volatility during the pandemic years. Nevertheless, the two main earning segments have experienced solid growth in average fees. Clinics' segment posted a 4Q average fee CAGR between 2017 and 2024 of 7.6%, which is mostly due to pricing power. The CAGR of the hospital segment, at 8.2% is partially due to the higher levels of complexity of services offered, which is also the case for the dentistry segment.



Source: Company data, Erste Group Research

Major revenue growth for main contributors

The combination of the factors described above led to a very high revenue CAGR when looking at fourth quarters of the last seven years. Clinics had a 30.5% CAGR revenue growth and hospitals had a similar CAGR of almost 33%, which is entirely remarkable, while all revenue CAGRs for all segments are in the double-digit range (with the exception of the corporates segment, sitting at a still very good 9.2%).



Source: Company data, Erste Group Research

Higher y-o-y operating costs...


On a yearly basis, IFRS 2024 operating costs grew y-o-y by 21.2%, on a 23% increase in total revenues while on a pro-forma basis, the same increased by 20% on a 21% growth in revenue (see above). On IFRS, large increases were recorded in personnel related expenses, with wages and social costs growing 19%- and third-party costs increasing by 22.5%, on the back of acquisitions and the inflationary upward pressure on wages and benefits. Consumables and commodities grew overall at 21.3%, a





2024 0/

tapering of the trend observed during the second part of last year, with higher increases in chemotherapy drugs consumables, balanced by a slight decrease in commodities. Marketing expenses also registered a 29.5% hike, in line with the strategy of consolidate and increase brand value. Depreciation also grew about 26%, as a result of the consolidation of the new companies and the increase in own developed projects.



Source: Company data, Erste Group Research

Out of the total y-o-y YE24 vs YE23 expense growth, third party expenses accounted for 31% of the increase in total operating costs, with wages and social costs accounting for 28%, and consumables and commodities around 31% of the total increase in operating costs, with depreciation about 11% and the rest of the items contributing minor amounts.

												4Q24 %
									% of tota	al rev.		of y-o-y
Opex breakdown (RON,mn.)	4Q24	4Q23	chng (%)	3Q24 (chng (%)	4Q22	chng (%)	4Q24	4Q23	3Q24	4Q22	cost incr
Wages & social	185.68	145.62	27.5%	167.32	11.0%	125.07	48.5%	25.1%	25.0%	25.0%	26.3%	28%
Third party	205.2	168.84	21.5%	184.6	11.2%	128.24	60.0%	27.7%	29.0%	27.5%	27.0%	25%
Consum.& commod.	200	155.7	28.5%	181.4	10.3%	142.99	39.9%	27.0%	26.8%	27.1%	30.1%	31%
Rent, utilit, maint, ins.	19.24	19.27	-0.2%	19.54	-1.5%	7.06	172.5%	2.6%	3.3%	2.9%	1.5%	0%
Promotion, comm.	16.5	11.36	45.2%	13.4	23.1%	8.5	94.1%	2.2%	2.0%	2.0%	1.8%	4%
Depreciation	72.3	56.5	28.0%	62.2	16.2%	49.75	45.3%	9.8%	9.7%	9.3%	10.5%	11%
Other	11.6	9.55	21.5%	7.4	56.8%	15.16	-23.5%	1.6%	1.6%	1.1%	3.2%	1%
Total	710.5	566.8	25.3%	635.9	11.7%	476.8	49.0%	96.0%	97.5%	94.8%	100.2%	100.0%
Labor costs	390.9	314.5	24.3%	351.9	11.1%	253.3	54.3%	52.8%	54.1%	52.5%	53.3%	


									2024 %
						%	of total rev.		of y-o-y
Opex breakdown (RON,mn.)	2024	2023	chng (%)	2022	chng (%)	2024	2023	2022	cost incr
Wages & social	669.6	562.6	19.0%	458.8	45.9%	24.6%	25.3%	25.4%	24%
Third party	766.1	625.3	22.5%	468.1	63.7%	28.1%	28.1%	25.9%	31%
Consum.& commod.	725.4	598.0	21.3%	521.2	39.2%	26.6%	26.9%	28.8%	28%
Rent, utilit, maint, ins.	78.38	72.16	8.6%	52.4	49.6%	2.9%	3.2%	2.9%	1%
Promotion, comm.	55.8	43.1	29.5%	31.8	75.5%	2.0%	1.9%	1.8%	3%
Depreciation	249.3	197.4	26.3%	152.4	63.6%	9.2%	8.9%	8.4%	11%
Other	37.5	31.8	17.9%	30.5	23.0%	1.4%	1.4%	1.7%	1%
Total	2582.1	2130.4	21.2%	1715.2	50.5%	94.8%	95.9%	94.8%	100.0%
Labor costs	1,435.7	1,187.9	20.9%	926.9	54.9%	52.7%	53.5%	51.2%	

Source: Company data, Erste Group Research

On a quarterly basis, the y-o-y dynamic remains largely similar with overall costs increasing 25.3% vs. the 26% growth in top line. Labor costs overall grew by 24.3%, and consumables and commodities by 21.3%. Y-o-y, the largest contribution to the cost increase remained third parties at 31% of total cost increase, with wages at 24% of total cost increases and




consumables and commodities at 28% of cost increases. Vs. the previous quarter, the increase in costs of 11.7% was higher than the advance in revenues (10%) however we do not discern any worrying trends, with all cost items relatively stable in terms of share of revenues. The exception is a small increase in the share of consumables and commodities, which is out of the management's scope of action.



Source: Company data, Erste Group Research

Margins retreated slightly compared to the previous quarter of 2024, showing rather a flattening, however the trend remains generally positive if calculated with a base in the worse quarter of 4Q22. Also, it is important to note that the previous negative margins in 2023 have been successfully reversed.



Source: Company data, Erste Group Research

On a positive trend

The solid YE24 y-o-y performance in profitability came on the back of 56% higher operating profit, that balanced the growth in net financing cots that increased by 12% y-o-y. Nevertheless, the dynamics of average fees and number of patients growth in absolute numbers shows what could continue to be a positive trend in respect to quarterly y-o-y growth of number of patients and average fees for clinics and hospitals, the largest revenue

generators for the company. The company doesn't release like-for-like data, and – as the acquisition targets are part of a diverse universe, it is difficult to assess if the variation in average fees is an intrinsic organic development, or the effect of acquisition of businesses with different characteristics and fee structure.

Marginally better than our expectations top line...

Overall revenues show better y-o-y growth compared to our expectations, with a top line coming at almost 23% growth compared to our more modest 19% growth forecast. The hospital segment revenues were showed the most upside vs our anticipation, growing 38% vs only 29% in our previous view. The number of patients treated grew more, and average fees grew marginally more. In the clinics segment as well, the number of patients jumped more than our forecast, by 13% compared to 10%, but the average fee growth was largely inline. The rest of the segments were basically in line with our forecasts, with minor variations.

Bussiness line	Bussiness line Rev growth (%)			wth (%)	Avg fees growth (%)		
	2024/2023	2024E/2023	2024/2023	2024E/2023	2024/2023	2024E/2023	
Clinics	23.0%	18.8%	13.0%	10.0%	8.8%	8.0%	
Stomatology	3.1%	3.5%	-0.1%	1.5%	3.2%	2.0%	
Hospitals	37.7%	28.8%	18.5%	12.0%	16.2%	15.0%	
Laboratories	28.0%	29.8%	18.1%	18.0%	8.4%	10.0%	
Corporate	14.4%	15.1%	-0.1%	1.0%	14.6%	14.0%	
Pharmacies	14.0%	10.7%	2.0%	-2.0%	11.9%	13.0%	
Other	8.2%	0.5%					
Total	22.8%	18.7%					

Source: Company data, Erste Group Research

... while profitability was in line

With top line 3.4% higher than our anticipation, and a 3.1% higher operating costs, EBITDA was 3.6% higher than our forecast and EBIT 9% higher, while operating and operating margins are largely in line with our previous view. (To note, the company had to pay a 1% turnover tax, since this amount is higher than the 16% tax rate of PBT)

INCOME ST. (RON, mn.)	2024	2024e c	:hng (%)
Sales	2715.5	2626.2	3.4%
Other operating income	9.0	7.9	14.4%
Operating income	2724.5	2634.1	3.4%
Operating expenses	2582.1	2503.3	3.1%
Operating profit	142.4	130.7	8.9%
EBITDA	391.7	378.2	3.6%
EBITDA margin	14.4%	14.4%	
Operating margin	5.2%	5.0%	

Source: Company data, Erste Group Research

Overall operating costs were marginally higher that our forecasts, on the back of higher revenues than our anticipations. It seems the company has employed more own talent compared to third parties vs our forecast, while most other cost increases came on the back of higher activity.

Opex breakdown (RON,mn.)	2024	2024e	(%)
Wages & social	669.6	640.1	4.6%
Third party	766.1	749.8	2.2%
Consum.& commod.	725.4	701.2	3.5%
Maint/Utilities/Comm	63.4	61.7	2.7%
Ins/Advertising	56.2	52.5	7.0%
Rents	14.6	16.4	-11.0%
Depreciation	249.3	247.4	0.8%
Other	37.5	34.1	9.8%
Total	2582.1	2503.3	3.1%
Labor costs	1435.7	1389.9	3.3%

Source: Company data, Erste Group Research



Lower IFRS gearing, and even better picture pro-forma

Net debt continued to increase, however the jump in EBITDA made gearing revert to a level lower than that of 2022. Moreover, on a pro-forma basis, the net debt to EBITDA ratio is below 4.

2016	2017	2018	2019	2020	2021	2022	2023	2024
20.7	79.2	34.2	38.9	82.0	136.0	89.1	100.3	113.0
27.4	41.8	63.0	103.2	114.7	136.6	160.6	211.7	264.0
213.1	252.9	313.5	478.6	561.8	590.5	1,028.5	1,349.8	1,487.9
219.9	215.5	342.4	542.9	594.6	591.1	1,100.0	1,461.2	1,638.9
3.95	2.77	3.59	3.67	2.80	2.07	4.46	5.04	4.18
	20.7 27.4 213.1 219.9	20.7 79.2 27.4 41.8 213.1 252.9 219.9 215.5	20.7 79.2 34.2 27.4 41.8 63.0 213.1 252.9 313.5 219.9 215.5 342.4	20.7 79.2 34.2 38.9 27.4 41.8 63.0 103.2 213.1 252.9 313.5 478.6 219.9 215.5 342.4 542.9	20.7 79.2 34.2 38.9 82.0 27.4 41.8 63.0 103.2 114.7 213.1 252.9 313.5 478.6 561.8 219.9 215.5 342.4 542.9 594.6	20.7 79.2 34.2 38.9 82.0 136.0 27.4 41.8 63.0 103.2 114.7 136.6 213.1 252.9 313.5 478.6 561.8 590.5 219.9 215.5 342.4 542.9 594.6 591.1	20.7 79.2 34.2 38.9 82.0 136.0 89.1 27.4 41.8 63.0 103.2 114.7 136.6 160.6 213.1 252.9 313.5 478.6 561.8 590.5 1,028.5 219.9 215.5 342.4 542.9 594.6 591.1 1,100.0	20.7 79.2 34.2 38.9 82.0 136.0 89.1 100.3 27.4 41.8 63.0 103.2 114.7 136.6 160.6 211.7 213.1 252.9 313.5 478.6 561.8 590.5 1,028.5 1,349.8 219.9 215.5 342.4 542.9 594.6 591.1 1,100.0 1,461.2

* - includes leasing and overdraft **- yearly EBITDA

Source: Company data, Erste Group Research

Looking forward: continuing to build...

During 2024, the company has grown organically, besides the acquisitions we list above. The MedLife Craiova Hospital, opened during 4Q24 for outpatient and daily hospitalization, and will expand to continuous hospitalization, operating block and intensive care providing advanced surgical capabilities, including a digital operating room and emergency room. The Medicis Hospital in Timisoara, is the 1st digitalized hospital in western Romania, represents a major investment of EUR25mn, and offers state-of-the art surgery capabilities. The company has opened two new fitness centers in Bucharest and two MindCare clinics. In the quest for increasing digitalization, it has integrated AI into the application for interpreting laboratory results.

... with confidence and caution...

The company states as strategic priorities the finalization of the 2nd stage of development of MedLife Craiova Hospital, the addition of a hyperclinic in central-south Romania; a new radiotherapy center, new mental health and fitness units. Also, it plans the consolidation of the Corporate business line, with new products, combining medical prevention and fitness. Additionally, it remains committed to non-organic growth on a selective basis, and while maintaining and NetDebt/EBITDA ratio of below 4, on an adjusted, normalized, pro-forma basis. Shareholders would be called to approve in March 2025 a supplementation of the syndicated loan by another EUR50mn.

... trying to hedge against a possible downturn

The stated strategy of the company, call for increasing the sophistication of services and integration of high-level digitalization and AI. This would add to a backbone of strategic development of hospitals and a concentration on oncology. Both are leading to a lesser exposure to an economic downturn as such services are vital or emergency treatments that cannot be postponed to a more benign economic cycle.

Erste Group Research CEE Equity Research - Company Update MedLife SA | Medical Equipment | Romania 21 March 2025

Page 11/16



Group Research

Head of Group Research Friedrich Mostböck, CEFA[®], CESGA[®] +43 (0)5 0100 11902 CEE Macro/Fixed Income Research +43 (0)5 0100 17357 Head: Juraj Kotian (Macro/FI) Katarzyna Rzentarzewska (Fixed income) Jakub Cery (Fixed income) +43 (0)5 0100 17356 +43 (0)5 0100 17384 Croatia/Serbia Alen Kovac (Head) Mate Jelić +385 72 37 1383 +385 72 37 1443 +385 72 37 2419 Ivana Rogic Czech Republic David Navratil (Head) Jiri Polansky +420 956 765 439 +420 956 765 192 +420 956 765 172 Michal Skorepa Hungary Orsolya Nyeste János Nagy +361 268 4428 +361 272 5115 Romania Ciprian Dascalu (Head) +40 3735 10108 +40 730 587 086 Ioana Birlan Eugen Sinca Vlad Nicolae Ionita +40 3735 10435 +40 7867 15618 Slovakia Maria Valachyova (Head) Matej Hornak Marian Kocis +421 2 4862 4185 +421 902 213 591 +421 904 677 274 Major Markets & Credit Research +43 (0)5 0100 17331 +43 (0)5 0100 16314 +43 (0)5 0100 19835 Head: Rainer Singer Ralf Burchert, CEFA®, CESGA® (Sub-Sovereigns & Agencies) Ralf Burchert, CEFA®, CESGA® (Sub-Sovereigns & Agencies) Hans Engel (Global Equities) Maurice Jiszda, CEFA®, CFDS® (USA, CHF) Peter Kaufmann, CFA® (Corporate Bonds) Heiko Langer (Financials & Covered Bonds) Stephan Lingmau (Global Equities) Maximilian Möstl (Credit Analyst Austria) Carmen Riefler-Kowarsch (Financials & Covered Bonds) Bernadett Povazsai-Römlid, CEFA®, CESGA® (Corporate Bonds) Elena Statelov, CIIA® (Corporate Bonds) Gerald Walek, CFA® (Eurozone) +43 (0)5 0100 19833 +43 (0)5 0100 19630 +43 (0)5 0100 11183 +43 (0)5 0100 85509 +43 (0)5 0100 16574 +43 (0)5 0100 17211 +43 (0)5 0100 17211 +43 (0)5 0100 19632 +43 (0)5 0100 17203 +43 (0)5 0100 19641 +43 (0)5 0100 16360 CEE Equity Research Head: Henning Eßkuchen, CESGA® Daniel Lion, CIIA[®] (Technology, Ind. Goods&Services) Michael Marschallinger, CFA[®] Nora Nagy (Telecom) Christoph Schultes, MBA, CIIA[®] (Real Estate) Thomas Unger, CFA[®] (Banks, Insurance) Vladimira Urbankova, MBA (Pharma) Martina Valenta, MBA CEE Equity Research +43 (0)5 0100 19634 +43 (0)5 0100 19034 +43 (0)5 0100 17420 +43 (0)5 0100 17906 +43 (0)5 0100 17416 +43 (0)5 0100 11523 +43 (0)5 0100 17344 +43 (0)5 0100 17343 +43 (0)5 0100 11913 Croatia/Serbia Mladen Dodig (Head) Boris Pevalek, CFA[®] Marko Plastic +381 11 22 09178 +385 99 237 2201 +385 99 237 5191 Bruno Barbic, CFA[®] Davor Spoljar, CFA[®] Magdalena Basic +385 99 237 1041 +385 72 37 2825 +385 99 237 1407 Czech Republic Petr Bartek (Head, Utilities) Jan Bystřický +420 956 765 227 +420 956 765 218 Hungary József Miró (Head) +361 235 5131 András Nagy Tamás Pletser, CFA[®] (Oil & Gas) +361 235 5132 +361 235 5135 Poland Cezary Bernatek (Head) Piotr Bogusz Łukasz Jańczak Jakub Szkopek Krzysztof Tkocz +48 22 257 5751 +48 22 257 5755 +48 22 257 5754 +48 22 257 5753 +48 22 257 5753 +48 22 257 5752 Romania Caius Rapanu +40 3735 10441 Ilie Pascaluta +40 7305 87324 Group Institutional & Retail Sales Group Institutional Equity Sales Head: Michal Rizek +420 224 995 537 Cash Equity Sales Werner Fuerst +43 (0)5 0100 83121 Viktoria Kubalcova +43 (0)5 0100 83124 Thomas Schneidhofer Oliver Schuster +43 (0)5 0100 83120 +43 (0)5 0100 83119 Institutional Equity Sales Croatia Matija Tkalicanac +385 72 37 21 14 Institutional Equity Sales Czech Republic +420 224 995 537 Head: Michal Rizek Jakub Brukner +420 731 423 294

Pavel Krabicka Martin Havlan	+420 224 995 411 +420 224 995 551
Institutional Equity Sales Hungary Levente Nándori Balázs Zánkay Krisztián Kandik	+361 235 5141 +361 235 5156 +361 235 5140
Institutional Equity Sales Poland Jacek Jakub Langer (Head) Tomasz Galanciak Wojciech Wysocki Przemysław Nowosad Maciej Senderek	+48 22 257 5711 +48 22 257 5715 +48 22 257 5714 +48 22 257 5712 +48 22 257 5713
Institutional Equity Sales Romania Valerian Ionescu	+40 3735 16541
Group Markets Retail and Agency Business Head: Martin Langer	+43 (0)5 0100 11313
Markets Retail Sales AT Head: Markus Kaller	+43 (0)5 0100 84239
Group Markets Execution Head: Kurt Gerhold	+43 (0)5 0100 84232
Retail & Sparkassen Sales Head: Uwe Kolar	+43 (0)5 0100 83214
Corporate Treasury Prod. Distribution Head: Martina KranzI-Carvell	+43 (0)5 0100 84147
Group Securities Markets Head: Thomas Einramhof	+43 (0)50100 84432
Institutional Distribution Core Head: Jürgen Niemeier	+49 (0)30 8105800 5503
Institutional Distribution DACH+ Head: Marc Friebertshäuser Bernd Bollhof Andreas Goll Mathias Gindele Ulrich Inhofner Sven Kienzle Rene Klasen Christopher Lampe-Traupe Michael Schmotz Christoph Ungerböck Klaus Vosseler	+49 (0)711 810400 5540 +49 (0)30 8105800 5525 +49 (0)711 810400 5561 +49 (0)711 810400 5562 +43 (0)5 0100 85544 +49 (0)711 810400 5541 +49 (0)30 8105800 5523 +43 (0)5 0100 85542 +43 (0)5 0100 85542 +49 (0)711 810400 5560
Slovakia Šarlota Šipulová Monika Směliková	+421 2 4862 5619 +421 2 4862 5629
Institutional Distribution CEE & Insti AM CZ Head: Antun Burić Jaromir Malak	+385 (0)7237 2439 +43 (0)5 0100 84254
Czech Republic Head: Ondrej Čech Milan Bartoš Jan Porvich Pavel Zdichynec	+420 2 2499 5577 +420 2 2499 5562 +420 2 2499 5566 +420 2 2499 5590
Croatia Head: Antun Burić Zvonimir Tukač Ana Tunjić Natalija Zujic	+385 (0)7237 2439 +385 (0)7237 1787 +385 (0)7237 2225 +385 (0)7237 1638
Hungary Head: Peter Csizmadia Gábor Bálint Balazs Papay Gergő Szabo Romania	+36 1 237 8211 +36 1 237 8205 +36 1 237 8213 +36 1 237 8209
Head: Cristian Vasile Pascu Institutional Asset Management Czech Republic	+40 373 511 695
Had: Petr Holeček Petra Maděrová David Petráček Blanca Weinerová Petr Valenta	+420 956 765 453 +420 956 765 178 +420 956 765 106 +420 956 765 809 +420 956 765 317 +420 956 765 140
Group Fixed Income Securities Markets Head: Goran Hoblaj	+43 (0)50100 84403
FISM Flow Head: Goran Hoblaj Margit Hraschek Bernd Thaler Ciprian Mitu Christian Kienesberger Zsuzsanna Toth	+43 (0)5 0100 84403 +43 (0)5 0100 84117 +43 (0)5 0100 84119 +43 (0)5 0100 85612 +43 (0)5 0100 84323 +36-1-237 8209
Poland Pawel Kielek Michal Jarmakowicz	+48 22 538 6223 +43 50100 85611



Page 12/16

Company description

Medlife is the leading private healthcare provider in Romania, operating the widest network of clinics, medical laboratories, mono and multidisciplinary hospitals and largest HPP client database in the country. The company operates 22 hyperclinics, 53 clinics, 10 hospitals, 13 stomatology centers, 5 maternities, a stem cell bank, 33 laboratories and more than 180 sampling points. It owns 20 pharmacies and services more than 705k HPP corporate clients.



Page 13/16

Disclaimer

This investment research (the "Document") has been prepared by Erste Group Bank AG or any of its consolidated subsidiaries (together with consolidated subsidiaries "Erste Group") independently and objectively for the purpose of providing additional economical information about the analyzed company or companies. The Document is based on reasonable knowledge of Erste Group's analyst in charge of producing the Document as of the date thereof and may be amended from time to time. It only serves for the purpose of providing non-binding information and does not constitute investment advice or marketing communication.

This Document does not constitute or form part of, and should not be construed as, an offer, recommendation or invitation to subscribe for or purchase any financial or connected financial instrument, and neither this Document nor anything contained herein shall form the basis of or be relied on in connection with or act as an inducement to enter into any contract or inclusion of a financial or connected financial instrument in a trading strategy. The document is also not a prospectus in the sense of the Prospectus Regulation, the Austrian Capital Market Act 2019 or comparable legal provisions. All information, analysis and conclusions provided herein are of general nature. This Document does not purport to provide a comprehensive overview about any investment, the potential risks and results nor does this Document take into account any individual needs of an investor (the "Investor") in relation to proceeds, tax aspects, risk awareness and appropriateness of the financial instrument or connected financial instruments. Therefore, this Document does not replace any investor- and investment-related evaluation nor any comprehensive risk disclosure; any financial instrument has a different risk level. Performance charts and example calculations do not provide any indication for future performance of a financial instrument resp. connected financial instruments. Information about past performance does not necessarily guarantee a positive development in the future and investments in financial instruments incl. connected financial instruments can be of risk and speculative nature. All projections, forecasts and price targets are clearly and prominently labelled as such, and the material assumptions made in producing or using them are indicated. Forecasts of future developments are based purely on estimates and assumptions. Actual future developments may differ from the forecast. Forecasts are therefore not a reliable indicator of future results and developments. The weaker the Company's credit-worthiness is, the higher the risk of an investment will be. Not every investment is suitable for every investor. Neither this document nor any of its components form the basis of any contract or commitment whatsoever. Therefore, Investors shall consult their advisors (in particular legal and tax advisors) prior to taking any investment decision to ensure that - irrespective of information provided herein - an intended transaction of a financial or connected financial instrument is appropriate for the Investor's needs and intention, that the Investor has understood all risks and that, after due examination, the Investor has concluded to make the investment and is in a position to bear the economical outcome of such investment. Investors are referred, for instance, to the suitability test according to the Austrian Securities Supervision Act 2018 and are advised to mind the client information pursuant to the Austrian Securities Supervision Act 2018. The performance of an investment is reduced by commissions, fees and other charges that depend on the individual circumstances of the investor. As a result of currency fluctuations, the investment result may increase or decrease.

Investment research is produced by Erste Group Research within the framework provided by applicable laws. The opinions featured in the equity and credit research reports may vary. Investors in equities may pursue different interests compared to those of investors on the credit side, related to the same issuer. The analyst has no authority whatsoever to make any representation or warranty on behalf of the analyzed company resp. issuer, Erste Group, one of its companies, or any other person. Care is taken, that all substantially material sources of information are clearly and prominently indicated. While all reasonable care has been taken to ensure that the facts stated herein are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, Erste Group (including its representatives and employees) neither expressly nor tacitly makes any guarantee as to or assumes any liability for the up-to-dateness, completeness and correctness of the content of this Document. Facts are clearly distinguished in the document from interpretations, estimates, opinions, and other types of non-factual information. Neither Erste Group nor any of its respective managing directors, supervisory board members, executive board members, directors, officers or other employees shall be in any way liable for any costs, losses or damages (including subsequent damages, indirect damages and loss of profit) howsoever arising from the use of or reliance on this Document.

Erste Group as well as representatives and employees principally may, to the extent permitted by law, have a position in stated financial instruments resp. connected financial instruments and may provide trading support or otherwise engage in transactions involving these financial instruments and/or connected financial instruments. Further, Erste Group as well as representatives and employees may principally offer investment banking services or advice to, or may take over management function in a company or issuer referred to in this Document.

This Document has been produced in line with Austrian law and for the territory of Austria. Forwarding this Document as well as marketing of financial instruments resp. connected financial instruments described herein are restricted or interdicted in certain jurisdictions. This, inter alia, applies to the United States, Canada, Switzerland, Australia, Korea and Japan. In particular, neither this Document nor any copy hereof may be taken or transmitted or distributed, directly or indirectly, into the United States or to US Persons (as defined in the U.S. Securities Act of 1933, as amended) unless applicable laws of the United States or certain federal states of the United States provide for applicable exemptions. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdiction. Persons receiving possession of this Document are obliged to inform themselves about any such restrictions and to adhere to them. By accepting this Document, the recipient agrees to be bound by the foregoing limitations and to adhere to applicable regulations. The document may not be reproduced or redistributed to other persons without the consent of Erste Group. Further information may be provided by Erste Group upon request. This Document and information provided herein at any time. Erste Group further reserves the right not to update any information provided herein or to cease updates at all. Misprints and printing errors reserved.

If one of the clauses provided for in this disclaimer is found to be illicit, inapplicable or not enforceable, the clause has to be treated separately from other clauses provided for in this disclaimer to the largest extent possible. In any case, the illicit, inapplicable or not enforceable clause shall not affect the licitness, applicability or enforceability of any other clauses.



Important Disclosures

THIS DOCUMENT MAY NOT BE BROUGHT INTO THE UNITED STATES OF AMERICA, CANADA, SWITZERLAND, AUSTRALIA, KOREA OR JAPAN, TO ANY PERSON WHO IS A CITIZEN OF THOSE STATES, OR SENT OR DISTRIBUTED TO ANY MEDIA IN ANY OF THOSE STATES.

General disclosures

All recommendations given by Erste Group Research are independent, objective and are based on the latest company, industry and other general information publicly available which Erste Group Research considers being reliable; however, Erste Group does not represent or assume any liability for the completeness of accuracy of such information or its recommendation. The best possible care and integrity is used to avoid errors and/or misstatements. No influence on the rating and/or target price is being exerted by either the covered company or other internal departments of Erste Group. Each research drawn up by an analyst is reviewed by a senior research executive or agreed with a senior analyst/deputy (4-eyes-principle). Erste Group has implemented extensive Compliance Rules on personal account dealings of analysts (please see "Conflicts of Interest"). Analysts are not allowed to involve themselves in any paid activities with the covered companies except as disclosed otherwise. No part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or views expressed by them contained in this document. Erste Group may engage in transactions with financial instruments, on a proprietary basis or otherwise, in a manner inconsistent with the view taken in this research report. In addition, others within Erste Group, including strategists and sales staff, may take a view that is inconsistent with that taken in this research report.

Conflicts of interest

Erste Group Bank AG ensures with internal policies that conflicts of interest are managed in a fair and reasonable manner. The policy "Managing Conflict of Interest in Connection with Investment Research" is provided under the following link: <u>https://www.erstegroup.com/legal/Managing_Conflicts_of_Interest_-Umgang_mit_IK.pdf</u>

Disclosures of potential conflicts of interest relating to Erste Group Bank AG and affiliated companies as well as relevant employees and representatives with respect to the issuer(s) resp. financial instruments are updated daily. An overview of conflicts of interest for all analysed companies by Erste Group Research is provided under the following link: Disclosure | Erste Group Bank AG.

Disclosure | Erste Group Bank AG.

The distribution of all recommendations and the distribution of recommendations in relation to which investment services have been provided is available under the following link:

https://www.erstegroup.com/legal/Recommendations_Distribution.pdf



Page 15/16

Erste Group rating definitions

Buy	> +20% from target price
Accumulate	+10% < target price < +20%
Hold	0% < target price < +10%
Reduce	-10% < target price < 0%
Sell	< -10% from target price

Our target prices are established by determining the fair value of stocks, taking into account additional fundamental factors and news of relevance for the stock price (such as M&A activities, major forthcoming share deals, positive/negative share/sector sentiment, news) and refer to 12 months from now. All recommendations are to be understood relative to our current fundamental valuation of the stock. The recommendation does not indicate any relative performance of the stock vs. a regional or sector benchmark.

A history of all recommendations within the last 12 months is provided under the following link:

Research Disclaimer | Erste Group Bank AG

Explanation of valuation parameters and risk assessment

Unless otherwise stated in the text of the financial investment research, target prices in the publication are based on a discounted cash flow valuation and/or comparison of valuation ratios with companies seen by the analyst as comparable or a combination of the two methods. The result of this fundamental valuation is adjusted to reflect the analyst's views on the likely course of investor sentiment. Whichever valuation method is used there is a significant risk that the target price will not be achieved within the expected timeframe. Risk factors include unforeseen changes in competitive pressures or in the level of demand for the company's products. Such demand variations may result from changes in technology, in the overall level of economic activity or, in some cases, from changes in social values. Valuations may also be affected by changes in taxation, in exchange rates, in the capital market sentiment and in regulatory provisions. Investment in overseas markets and instruments such as ADRs can result in increased risk from factors such as exchange rates, exchange controls, taxation, political, economic and social conditions.

All market prices within this publication are closing prices of the previous trading day (unless otherwise mentioned within the publication). Detailed information about the valuation and methodology of investment research by the Erste Group Bank AG is provided under the following link: <u>https://www.erstegroup.com/legal/Bewertungsmethoden_and_Valuations.pdf</u>

Planned frequency of updates

Target prices for individual stocks are meant to be 12 month target prices, starting from the date of the publication. Target prices and recommendations are reviewed usually upon release of quarterly reports, or whenever circumstances require.

Periodical publications are identified by their respective product name and indicate update frequency as such (e.g. Quarterly). Recommendations mentioned within these publications are updated in an according frequency, unless otherwise mentioned (e.g. a 12M TP is not updated on a monthly base, even when mentioned in summarizing monthly/quarterly product).

If a recommendation change has been made in this publication, please see the following link for a detailed overview of the previous recommendation(s): https://www.erstegroup.com/en/research/research-legal



Page 16/16

Links

Erste Group may provide hyperlinks to websites of entities mentioned in this document, however the inclusion of a link does not imply that Erste Group endorses, recommends or approves any material on the linked page or accessible from it. Erste Group does not accept responsibility whatsoever for any such material, including in particular the completeness and accuracy, nor for any consequences of its use.

Additional notes to readers in the following countries:

Austria: Erste Group Bank AG is registered in the Commercial Register at Commercial Court Vienna under the number FN 33209m. Erste Group Bank AG is authorized and regulated by the European Central Bank (ECB) (Sonnemannstraße 22, D-60314 Frankfurt am Main, Germany) and by the Austrian Financial Market Authority (FMA) (Otto-Wagner Platz 5, A-1090, Vienna, Austria).

Germany: Erste Group Bank AG is authorised for the conduct of investment business in Germany by the Austrian Financial Market Authority (FMA) and subject to limited regulation by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

United Kingdom (UK): Erste Group Bank AG is regulated for the conduct of investment business in the UK by the Financial Conduct Authority and the Prudential Regulation Authority. This document is directed exclusively to eligible counterparties and professional clients. It is not directed to retail clients. No persons other than an eligible counterparty or a professional client should read or rely on any information in this document. Erste Group Bank AG does not deal for or advise or otherwise offer any investment services to retail clients.

Czech Republic: Česká spořitelna, a.s. is regulated for the conduct of investment activities in Czech Republic by the Czech National Bank (CNB).

Croatia: Erste Bank Croatia is regulated for the conduct of investment activities in Croatia by the Croatian Financial Services Supervisory Agency (HANFA).

Hungary: Erste Bank Hungary ZRT. And Erste Investment Hungary Ltd. Are regulated for the conduct of investment activities in Hungary by the Hungarian Financial Supervisory Authority (PSZAF).

Serbia: Erste Group Bank AG is regulated for the conduct of investment activities in Serbia by the Securities Commission of the Republic of Serbia (SCRS).

Romania: Banka Comerciala Romana is regulated for the conduct of investment activities in Romania by the Romanian National Securities Commission (CNVM).

Poland: Erste Securities Polska S.A. is regulated for the conduct of investment activities in Poland by the Polish Financial Supervision Authority (PFSA).

Slovakia: Slovenská sporiteľňa, a.s. is regulated for the conduct of investment activities in Slovakia by the National Bank of Slovakia (NBS).

Switzerland: This research report does not constitute a prospectus or similar communication in connection with an offering or listing of securities as defined in Articles 652a, 752 and 1156 of the Swiss Code of Obligation and the listing rules of the SWX Swiss Exchange.

Hong Kong: This document may only be received in Hong Kong by 'professional investors' within the meaning of Schedule 1 of the Securities and Futures Ordinance (Cap.571) of Hong Kong and any rules made there under.

© Erste Group Bank AG 2025. All rights reserved.

Published by:

Erste Group Bank AG Group Research 1100 Vienna, Austria, Am Belvedere 1 Head Office: Vienna Commercial Register No: FN 33209m Commercial Court of Vienna Erste Group Homepage: www.erstegroup.com